Cell therapy trial shows ‘significant’ vision restoration
ReNeuron has found ‘significant restoration of vision’ in patients with retinitis pigmentosa given its human retinal progenitor cells (hRPC) cell therapy.
Read More
Tag: ReNeuron
ReNeuron wins £1.8 million for cell therapy development
Innovate UK grant will help advance its manufacturing capabilities
Read More
Study shows long-term benefit with ReNeuron’s stroke therapy
ReNeuron’s CTX cell therapy candidate has been shown to improve neurological function in patients with stable motor disability following a stroke for at least 24 months, according to long-term data from a Phase I trial published by The Lancet.
Read More
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
